Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Moodys
Baxter
Johnson and Johnson
Medtronic

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for INC280


Email this page to a colleague

« Back to Dashboard

What is the drug development status for INC280?

INC280 is an investigational drug.

There have been 36 clinical trials for INC280. The most recent clinical trial was a Phase 2 trial, which was initiated on September 25th 2020.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Array BioPharma, and National Cancer Institute (NCI).

There are one hundred and one US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for INC280
TitleSponsorPhase
Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLCNovartis PharmaceuticalsPhase 2
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyNovartis PharmaceuticalsPhase 3
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationNovartis PharmaceuticalsPhase 2

See all INC280 clinical trials

Clinical Trial Summary for INC280

Top disease conditions for INC280
Top clinical trial sponsors for INC280

See all INC280 clinical trials

US Patents for INC280

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
INC280 ⤷  Sign up for a Free Trial Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA) ⤷  Sign up for a Free Trial
INC280 ⤷  Sign up for a Free Trial Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma Massachusetts Eye and Ear Infirmary (Boston, MA) ⤷  Sign up for a Free Trial
INC280 ⤷  Sign up for a Free Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Sign up for a Free Trial
INC280 ⤷  Sign up for a Free Trial Methods of treating pediatric cancers Loxo Oncology, Inc. (Stamford, CT) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for INC280

Drugname Country Document Number Estimated Expiration Related US Patent
INC280 European Patent Office EP3131552 2034-04-16 ⤷  Sign up for a Free Trial
INC280 Spain ES2823756 2034-04-16 ⤷  Sign up for a Free Trial
INC280 Japan JP2017514806 2034-04-16 ⤷  Sign up for a Free Trial
INC280 Japan JP2019070012 2034-04-16 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Moodys
Baxter
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.